Moderna Stock News

https://www.investing.com/analysis/moderna-is-the-stock-still-a-buy-as-governments-move-to-end-covid-restrictions-200618514

A new choice for childhood vaccinations will be rolled out from tomorrow.

Children aged six to 11 years can get a Moderna COVID-19 vaccine from tomorrow, after it was given the final green light.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips MRNA stock has fallen into the buy zone, providing a prime opportunity as Moderna develops and commercializes multiple vaccine products. The post Moderna Offers Deep Value as Drug Pipeline Flows Fast appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. Get in Now on Tiny $3 Forever Battery Stock Interested in Crypto? Read This First

The story for this biotech is far from over -- but its path ahead may be more complicated.

Shares of Moderna Inc. gained 3.0% in trading on Monday after the company said it began a Phase 3 clinical trial evaluating its respiratory syncytial virus vaccine candidate. RSV is a common, seasonal respiratory virus that causes cold symptoms; it is more likely to become serious in children and older adults. The study is expected to test the experimental vaccine in about 34,000 adults who are at least 60 years old. "Our ultimate goal is to combine our RSV vaccine with our COVID-19 and flu boosters into a single-dose booster," Moderna CEO Stéphane Bancel said in a news release. Moderna''s stock is down 6.0% over the past year, while the broader S&P 500 has gained 11.1%. Market Pulse Stories are Rapid-fire, short news bursts on stocks and markets as they move. Visit MarketWatch.com for more information on this news.

Spains embassy in Beijing is to make a limited number of non-Chinese Covid-19 vaccine doses available for Spaniards based in China.The embassy said on Tuesday that the vaccines, supplied by US firm Moderna, had arrived in China and were to be used only as boosters. They are expected to be administered in the first week of March in the embassy premises.But the Moderna booster shots will not be recognised as proof of vaccination in Chinas Covid-19 health code app, which is required for travel

Moderna (MRNA) has been given the green light by a Data and Safety Monitoring Board to begin the phase 3 trial of its Respiratory Syncytial Virus.

InvestorPlace - Stock Market News, Stock Advice & Trading Tips MRNA stock is seen purely as a Covid-19 play. Until Moderna can prove it''s not a one-hit wonder, shares are likely to remain depressed. The post Is Moderna the Next Gilead or the Next Regeneron? appeared first on InvestorPlace . More From InvestorPlace Stock Prodigy Who Found NIO at $2 Says Buy THIS Now Man Who Called Black Monday: Prepare Now. Get in Now on Tiny $3 Forever Battery Stock Interested in Crypto? Read This First

The market is closed on Monday. Earnings reports from Home Depot, Alibaba, Booking, Stellantis, Coinbase, Moderna, Newmont, and more. Plus, PMIs and consumer confidence data.

The market is closed on Monday. Earnings reports from Home Depot, Alibaba, Booking, Stellantis, Coinbase, Moderna, Newmont, and more. Plus, PMIs and consumer confidence data.

FDA Weighs Authorizing Second COVID Booster Jab Despite repeated warnings from the WHO that emerging nations should be given priority access to the mRNA vaccines produced by Moderna and Pfizer, American authorities are looking at potentially authorizing a second doses for at least some patients as they further consider whether to recommend annual boosters. The planning is still in its early stages, and authorization would ultimately depend on ongoing studies establishing that a fourth dose would shore up people''s molecular defenses, which have waned after their first booster and reduced their risk of symptomatic and severe disease. Among the issues that need to be resolved, according to WSJ''s source, are whether the second booster dose should be authorized for all adults or particular age groups, and whether it should target the omicron variant specifically, or be formulated differently. Whether the fourth booster could ultimately be the start of annual COVID vaccinations is also under consideration; no decision is final, and it could be necessary to make booster shots available earlier if a more dangerous, elusive variant were to emerge.

Biotech stock extended lower for a second straight week as risk aversion continued to pressure stocks amid geopolitical tensions and macroeconomic worries. On the regulatory front, the Food and Drug Administration approved Agios Pharmaceuticals, Inc.''s (NASDAQ: AGIO ) mitapivat for treating pyruvate kinase deficiency, a rare, inherited metabolic disorder. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) stock tumbled close to 60% after an FDA panel found that data included in the company''s new drug application for pain drug tramadol was inadequate to support approval. GlaxoSmithKline plc (NYSE: GSK ) and Sanofi (NASDAQ: SNY )- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) suffered setbacks after their respective late-stage studies of respiratory syncytial vaccine candidate in pregnant women and Dupixent as a treatment option for skin rash had to be halted. Here are the key catalysts for the unfolding week: Conferences 49th Annual Scientific and Technology Meeting of the American Auditory Society, AAS (hybrid event) Feb. 24-27, in Scottsdale, Arizona & online Multidisciplinary Head and Neck Cancers Symposium (virtual event): Feb. 24-27, in Phoenix, Arizona & online International Society of Nephrology''s World Congress of Nephrology, or WCN, 2022 (hybrid event): Feb. 24-27, in Kuala Lumpur & online PDUFA Dates The FDA has set a PDUFA date of Friday, Feb. 25, for its new drug application for Reata Pharmaceuticals, Inc.''s (NASDAQ: RETA ) Bardoxolone.

The following is a list of earnings slated for release February 21-25, along with a few previews.